Parameter | Previously treated | Treatment naive |
Entire group, n | 1181 | 1555 |
Mean baseline BCVA, logMAR | 0.52±0.42 | 0.57±0.44 |
Mean BCVA at follow-up, logMAR | 0.53±0.44 (p=0.14) | 0.56±0.43 (p=0.18) |
Phakic status at baseline, n (%) | 743 (62.9) | 1005 (64.6) |
Cataract at baseline, n (%) | 317 (42.6) | 280 (27.8) |
Cataract progression or development, n (%) | 186 (25.0) | 139 (13.8) |
Conduction of cataract surgery, n (%) | 236 (31.7) | 280 (27.8) |
Prior history of glaucoma, n (%) | 90 (7.6) | 65 (4.2) |
Prior treatment with AGM, n (%) | 75 (6.4) | 56 (3.6) |
Total cases of glaucoma, n (%) | 303 (25.7) | 385 (24.8) |
Need for AGM, n (%) | 277 (91.4) | 351 (91.2) |
Need for surgery, n (%) | 13 (4.3) | 12 (3.1) |
Endophthalmitis, n (%) | 0 (0) | 2 (0.1) |
Vitreous haemorrhage, n (%) | 0 (0) | 1 (0.06) |
Retinal detachment, n (%) | 1 (0.08) | 0 (0) |
AGM, anti-glaucoma medications; BCVA, best corrected visual acuity.